Law360, New York (May 1, 2012, 5:11 PM EDT) -- Pfizer Inc. said Tuesday that it has settled Brigham Young University's long-running contract and trade secrets lawsuit that claimed one of the school's professors discovered the enzyme behind the development of the drugmaker's anti-inflammatory drugs Bextra and Celebrex.
Both parties declined to release details of the settlement, which had not yet been filed with the District of Utah federal court at press time.
The settlement will resolve close to six years of litigation in which BYU accused Pfizer of breaching two parts of a research agreement originally signed by the university and co-defendant Monsanto Co., the pharmaceutical wing of which is...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!